In October of 2016, the Australian Government announced the commencement of the Narcotics Drugs Amendment Act 2016 which now gives patients and doctors access to safe, reliable and legal source of cannabis for medicinal use.
As a result of this change in legislation, businesses in Australia can now apply for a licence to cultivate cannabis for medicinal purposes, to manufacture medicinal cannabis products or to conduct medicinal cannabis related research under the Medicinal Cannabis Scheme.
Medicinal Organic Cannabis Australia (MOCA) holds various licences from the State and Federal Governments which allow the Company to import and export wholesale cannabis medication into and out of Australia. MOCA operates its wholesale activities and distribution out of one of the largest licensed pharmaceutical complexes in Australasia.
The Company has been working with the New Zealand Government since changes to federal legislation in December 2018 and has commenced approved research into medical cannabis cultivation. MOCA is now funding growth for developing its facility for cultivation and manufacture of cannabis based medications.
Business Strategy Medical Cannabis
The Company enjoys significant growth in the Australian and New Zealand medicinal cannabis market. Our focus is on becoming a leading national and international producer, wholesaler and retailer of cannabis based products by expanding rapidly to meet the expected demand. We are achieving this by:
· Building our range of wholesale MOCA branded cannabis based products in Australia.
· Working with the 'best in field' for logistics and distribution of our medical cannabis products.
· Working closely with wholesale clients including hospitals, medical practitioners and cannabis clinics in Australia.
· Expanding our health care client base in Australia and New Zealand through digital promotions and practitioner partnerships.
· Establishing a licensed wholesale cannabis distribution facility in New Zealand to cater to the emerging market.
· Establish a cannabis cultivation facility in New Zealand to support our branded wholesale market.
· Expand our cultivation base in Europe exponentially to cater to international demand.
By controlling our cultivation and production process, we can support our online and offline distribution network and constantly improve our quality and pricing.
Over the next one to three years, we will grow the business through the manufacture of organic products and development of the MOCA brand.
During this period, the Company will operate on a staged approach to leverage its licences and continue to bring a variety of federally approved medical cannabis products into our secure pharmaceutical facility in New South Wales, including CBD and THC capsules, CBD oils and tinctures, sublinguals and concentrates. Our import licence enable us to wholesale our cannabis products to pharmacies, hospitals and licenced medical professionals. Our export licence enables the Company to sell products to licenced buyers around the world.
The Company, in conjunction with the New Zealand Government will establish licences for importation, wholesale, import and to establish a cultivation facility firstly for research and secondly for cultivation of marijuana for commercial sale.
The company is seeking investment for our New Zealand cannabis cultivation facility which will also serve as a wholesale distribution centre to service the local market.
Our Business Model
Our main source of revenue, in the first instance is in the wholesale of cannabis medications to the healthcare industry in Australia and abroad.
We are specifically targeting medical cannabis clinics and licenced doctors. The Company has developed educational material and brochures for medical professionals to assist in prescribing MOCA cannabis products. The Company is also targeting emerging nations with approved medical marijuana for wholesale supply of products.
In the second instance we will generate revenue from the cultivation of raw and refined cannabis, our research licence is conditionally approved by the New Zealand Government.
Our Value Proposition
MOCA’s target audience, is a rapidly growing global market of people who seek wellness and relief from illness and an enhanced quality of life.
Around the world, patients are seeking innovative emerging medical solutions to restore health and alleviate sickness.
MOCA is supplying the Australian market with high quality, sustainable, organically grown cannabis medication.
Business Objectives for Medicinal Organic Cannabis Australia (MOCA)
Our objectives are to import MOCA branded cannabis based medication from our international partners into Australia and supply an emerging market.
Secondly, we are developing facilities to cultivate, produce and manufacture medical organic cannabis products utilizing the technology and know how of our partners. The business is orientated and based in Australia, Europe and New Zealand and has a strong focus on exporting to international markets.